Table 2.
Plasma Lipid mediator concentrations.
| Control (pg/mL) | CRSwNP (pg/mL) | URTI (pg/mL) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| DHA metabolome | mean | ± | sem | mean | ± | sem | mean | ± | sem | ||
| RvD1 | 0.05 | ± | 0.06 | 0.12 | ± | 0.08 | 1.17 | ± | 0.41 | ||
| 17R-RvD1 | – | 0.04 | ± | 0.03 | 0.21 | ± | 0.21 | ||||
| RvD2 | 133.94 | ± | 86.45 | 30.44 | ± | 18.38 | 465.20 | ± | 194.48 | ||
| RvD3 | 0.03 | ± | 0.02 | – | – | ||||||
| 17R-RvD3 | 1.49 | ± | 1.20 | 0.01 | ± | 0.01 | – | ||||
| RvD4 | – | – | – | ||||||||
| RvD5 | 0.19 | ± | 0.11 | 0.03 | ± | 0.03 | 1.48 | ± | 1.22 | ||
| RvD6 | – | – | 0.18 | ± | 0.18 | ||||||
| PD1 | 0.29 | ± | 0.25 | 0.61 | ± | 0.27 | 0.78 | ± | 0.58 | ||
| 10S,17S-diHDAH | 0.59 | ± | 0.35 | – | 0.66 | ± | 0.43 | ||||
| 22-OH-PD1 | 2.05 | ± | 2.12 | – | – | ||||||
| 17R-PD1 | 0.32 | ± | 0.29 | 0.32 | ± | 0.26 | 0.24 | ± | 0.18 | ||
| MaR1 | 2.25 | ± | 1.33 | 0.75 | ± | 0.41 | 1.95 | ± | 0.97 | ||
| 7S,14S-diHDHA | 0.84 | ± | 0.73 | 0.18 | ± | 0.18 | – | ||||
| MaR2 | – | 0.08 | ± | 0.06 | – | ||||||
| 22-OH-MaR1 | 0.65 | ± | 0.46 | – | – | ||||||
| 22-COOH-MaR1 | – | – | – | ||||||||
| 14-oxo-MaR1 | – | – | – | ||||||||
| 4,14-diHDHA | – | – | – | ||||||||
| n-3 DPA metabolome | |||||||||||
| RvT1 | – | 0.36 | ± | 0.26 | – | ||||||
| RvT2 | 0.04 | ± | 0.04 | 0.03 | ± | 0.02 | 0.06 | ± | 0.06 | ||
| RvT3 | 0.07 | ± | 0.07 | 1.29 | ± | 0.95 | 0.53 | ± | 0.26 | ||
| RvT4 | 0.66 | ± | 0.35 | 0.05 | ± | 0.03 | 2.37 | ± | 1.89 | ||
| RvD1 n-3 DPA | 0.55 | ± | 0.57 | 1.26 | ± | 1.01 | 0.20 | ± | 0.20 | ||
| RvD2 n-3 DPA | 0.21 | ± | 0.15 | 0.04 | ± | 0.04 | – | ||||
| RvD5 n-3 DPA | 0.55 | ± | 0.35 | 0.39 | ± | 0.28 | – | ||||
| PD1 n-3 DPA | 0.90 | ± | 0.87 | – | – | ||||||
| PD2 n-3 DPA | – | – | – | ||||||||
| 10S, 17S-diHDPA | 0.47 | ± | 0.49 | – | – | ||||||
| 22-OH-PD1n-3 DPA | – | – | – | ||||||||
| MaR1 n-3 DPA | 0.09 | ± | 0.09 | – | 0.61 | ± | 0.40 | ||||
| MaR2 n-3 DPA | 7.05 | ± | 2.38 | – | – | ||||||
| 7S,14S-diHDPA | – | – | – | ||||||||
| EPA metabolome | |||||||||||
| RvE1 | 4.39 | ± | 4.37 | 0.04 | ± | 0.04 | – | ||||
| RvE2 | – | 0.19 | ± | 0.07 | 0.10 | ± | 0.10 | ||||
| RvE3 | – | – | 1.41 | ± | 1.41 | ||||||
| AA metabolome | |||||||||||
| LXA4 | – | 0.04 | ± | 0.02 | 1.20 | ± | 0.92 | ||||
| LXB4 | 5.76 | ± | 4.44 | – | 5.69 | ± | 5.69 | ||||
| 5S,15S-diHETE | 0.13 | ± | 0.09 | 13.40 | ± | 9.04 | – | ||||
| 13,14-dehydro-15-oxo-LXA4 | |||||||||||
| 15-oxo-LX4 | 0.02 | ± | 0.01 | 0.39 | ± | 0.39 | |||||
| 15-epi-LXA4 | 0.22 | ± | 0.17 | 0.06 | ± | 0.03 | 1.49 | ± | 1.49 | ||
| 15-epi-LXB4 | 2.28 | ± | 1.76 | 0.08 | ± | 0.08 | 5.69 | ± | 5.69 | ||
| LTB4 | 7.96 | ± | 4.97 | 7.56 | ± | 1.87 | 8.53 | ± | 3.84 | ||
| 5S,12S-diHETE | 7.41 | ± | 5.19 | 3.19 | ± | 1.91 | 2.48 | ± | 1.76 | ||
| 6-trans-LTB4 | 1.57 | ± | 1.18 | 2.13 | ± | 1.10 | 2.36 | ± | 1.61 | ||
| 6-trans-12-epi LTB4 | 0.06 | ± | 0.07 | 0.14 | ± | 0.07 | – | ||||
| 20-OH-LTB4 | 0.00 | ± | 0.00 | 0.94 | ± | 0.42 | 0.59 | ± | 0.59 | ||
| 20-COOH-LTB4 | 0.43 | ± | 0.30 | 0.62 | ± | 0.26 | 2.08 | ± | 2.08 | ||
| PGE2 | 2.47 | ± | 1.60 | 4.24 | ± | 0.96 | 5.43 | ± | 2.34 | ||
| PGD2 | 5.72 | ± | 3.53 | 3.39 | ± | 0.80 | 3.39 | ± | 1.15 | ||
| PGF2a | 1.05 | ± | 0.84 | 3.45 | ± | 1.03 | 3.89 | ± | 1.56 | ||
| TxB2 | 28.68 | ± | 23.94 | 71.19 | ± | 28.47 | 29.88 | ± | 15.95 | ||
Plasma was collected from patients with CRSwNP (n = 24) healthy volunteers (n =15) and subjects with URTI and LM were extracted using C18 SPE and LM concentrations determined using LC-MS/MS based LM profiling. - = Below limits.